Home  /  Resource Library  /  COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA: RESULTS OF THE RANDOMIZED PHASE 2 KEYFORM-008 STUDY

COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA: RESULTS OF THE RANDOMIZED PHASE 2 KEYFORM-008 STUDY

EHA 2026